Table 3. Analysis of relevant factors for recurrence of HCC in 50 patients.
| Variables | Count (%) | Recurrence (%) | ꭓ2 | P value | |
|---|---|---|---|---|---|
| Yes | No | ||||
| Age, years | 1.317 | 0.251 | |||
| <50 | 22 (6.7) | 7 (2.1) | 15 (4.6) | ||
| ≥50 | 28 (8.5) | 5 (1.5) | 23 (7.0) | ||
| Gender | 0.658 | 0.417 | |||
| Male | 48 (14.6) | 12 (3.7) | 36 (11.0) | ||
| Female | 2 (0.6) | 0 (0) | 2 (0.6) | ||
| Tumor size (cm) | 13.773 | 0.000 | |||
| ≤6.5 | 31 (9.5) | 2 (0.6) | 29 (8.8) | ||
| >6.5 | 19 (5.8) | 10 (3.0) | 9 (2.7) | ||
| Tumor amount | 3.559 | 0.059 | |||
| ≤3 | 39 (11.9) | 7 (2.1) | 32 (9.8) | ||
| >3 | 11 (3.4) | 5 (1.5) | 6 (1.8) | ||
| PVT | 2.515 | 0.113 | |||
| No | 41 (12.5) | 8 (2.4) | 33 (10.1) | ||
| Yes | 9 (2.7) | 4 (1.2) | 5 (1.5) | ||
| Milan criteria | 5.469 | 0.019 | |||
| No | 27 (8.2) | 10 (3.0) | 17 (5.2) | ||
| Yes | 23 (7.0) | 2 (0.6) | 21 (6.4) | ||
| UCSF criteria | 9.914 | 0.002 | |||
| No | 22 (6.7) | 10 (3.0) | 12 (3.7) | ||
| Yes | 28 (8.5) | 2 (0.6) | 26 (7.9) | ||
| Pre-transplantation treatment | 4.488 | 0.481 | |||
| TACE | 10 (3.0) | 3 (0.9) | 7 (2.1) | ||
| Resection | 2 (0.6) | 1 (0.3) | 1 (0.3) | ||
| RFA | 14 (4.3) | 1 (20.3) | 13 (4.0) | ||
| Resection with TACE | 1 (0.3) | 0 | 1 (0.3) | ||
| Resection with TACE and RFA | 1 (0.3) | 0 | 1 (0.3) | ||
| None | 22 (6.7) | 7 (2.1) | 15 (4.6) | ||
| AFP (ìg/L) | 1.754 | 0.185 | |||
| ≤27 | 25 (7.6) | 4 (1.2) | 21 (6.4) | ||
| >27 | 25 (7.6) | 8 (2.4) | 17 (5.2) | ||
| HBsAg | 0.010 | 0.921 | |||
| Negative | 12 (3.7) | 3 (0.9) | 9 (2.7) | ||
| Positive | 38 (11.6) | 9 (2.7) | 25 (7.6) | ||
| Cirrhosis | 3.185 | 0.074 | |||
| No | 3 (0.3) | 2 (0.6) | 1 (0.3) | ||
| Yes | 47 (14.3) | 10 (3.0) | 37 (11.3) | ||
| Tumor grade* | 1.709 | 0.426 | |||
| Grade I | 5 (1.5) | 0 (0) | 5 (1.5) | ||
| Grade II | 24 (7.3) | 6 (1.8) | 18 (5.5) | ||
| Grade III | 21 (6.4) | 6 (1.8) | 15 (4.6) | ||
| TNM staging | 4.486 | 0.214 | |||
| I | 4 (1.2) | 0 | 4 (1.2) | ||
| II | 16 (4.9) | 2 (0.6) | 14 (4.3) | ||
| III | 29 (8.8) | 10 (3.0) | 19 (5.8) | ||
| IV | 1 (0.3) | 0 | 1 (0.3) | ||
| CTCs | 6.211 | 0.013 | |||
| >1 | 26 (7.9) | 10 (3.0) | 16 (4.9) | ||
| 0 | 24 (7.3) | 2 (0.6) | 22 (6.7) | ||
| MVI | 2.515 | 0.113 | |||
| Yes | 9 (2.7) | 4 (1.2) | 5 (1.5) | ||
| No | 41 (12.5) | 8 (2.4) | 33 (10.0) | ||
*, HCC cellular differentiation. HCC, hepatocellular carcinoma; PVT, portal vein thrombosis; TACE, transarterial chemoembolization; RFA, radiofrequency ablation; AFP, preoperative alpha-fetoproteins; HBsAg, hepatitis B surface antigen; CTC, circulating tumor cells.